Expert Interview
Looking at the Future of KRAS Inhibition in NSCLC Based on AACR 2026 Data from Revolution Medicines (Zoldonrasib), D3 Bio (Elisrasib) and Astellas (Setidegrasib)
Ticker(s): RVMD, ALPMF, D3 BioInstitution: UC San Diego Health
- Professor of Medicine & Lung Cancer Unit Leader at Moores Cancer Center, UC San Diego.
- Manages 250+ patients with lung cancer.
- Clinical practice and research focuses on lung cancer with a specific interest in cancer relating to females and non-smokers; active in numerous clinical trials.
How many patients do you manage with NSCLC?
Added By: lilly_adminOn a scale of 1 to 10 (with 10 being ecstatic), how excited are you for Zoldonrasib in NSCLC?
Added By: lilly_adminWhat do you see as the role of KRAS inhibition moving forward for NSCLC management?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
